Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PNMT | P11086 | 9/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557821 | 1.00 | MAPT (0.60) | MAPTALDH1A1PNMTADRA2AASIC3 | |
| SCHEMBL31335752 | 1.00 | MAPT (0.60) | MAPTALDH1A1PNMTADRA2AASIC3 | |
| SCHEMBL30997742 | 0.82 | ALDH1A1 (0.61) | MAPTALDH1A1TYMSPKM | |
| SCHEMBL22028064 | 0.82 | ALDH1A1 (0.61) | MAPTALDH1A1TYMSPKM | |
| SCHEMBL8258918 | 0.82 | PNMT (0.55) | MAPTALDH1A1PNMTADRA2AASIC3 | |
| SCHEMBL24040085 | 0.81 | PNMT (0.54) | MAPTALDH1A1PNMTADRA2AASIC3 | |
| SCHEMBL24869958 | 0.81 | PNMT (0.54) | MAPTALDH1A1PNMTADRA2AADRA2B | |
| SCHEMBL13875069 | 0.81 | PNMT (0.54) | MAPTALDH1A1PNMTADRA2AASIC3 | |
| SCHEMBL18875031 | 0.81 | PNMT (0.54) | MAPTALDH1A1PNMTADRA2AASIC3 | |
| SCHEMBL18875034 | 0.81 | PNMT (0.54) | MAPTALDH1A1PNMTADRA2AASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| CN-102388043-A | Histamine h3 inverse agonists and antagonists and methods of use thereof | SEPRACOR INC | 2012-03-21 | — | — | CN | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| EP-2396327-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-0832069-B1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER (US) | 2003-03-05 | — | — | EP | disclosed |
| CN-1380289-A | Amide capable of inhibiting ApoB-secretion/MTP | PFIZER (US) | 2002-11-20 | — | — | CN | disclosed |
| EP-1181954-A2 | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion | PFIZER INC. (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6121283-A | Apo B-secretion/MTP inhibitory amides | PFIZER INC (US) | 2000-09-19 | — | — | US | disclosed |
| CN-1238764-A | Amides inhibiting ApoB-secretion/MTP | PFIZER (US) | 1999-12-15 | — | — | CN | disclosed |
| EP-0944602-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5919795-A | ATHEROSCLEROSIS THERAPY | PFIZER INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998023593-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0832069-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | MAPT 738/4885ALDH1A1 2598/4885PNMT 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.